Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

Home
/
update
/
details

Bruker Corporation Invests in NovAliX to Accelerate Drug Discovery Innovations

NextEdge Admin

10 Aug 2024

2 min 34 sec

Bruker Corporation has made a strategic minority investment in NovAliX, a preclinical Contract Research Organization (CRO) specializing in drug discovery services, headquartered in Strasbourg, France. This investment aims to accelerate NovAliX's growth and expand its presence in Europe and the United States.

The collaboration between Bruker and NovAliX will focus on advancing drug discovery technologies, particularly in functional structural biology and biophysical methods for studying molecular dynamics, drug interactions, and therapeutic mechanisms of action. Leveraging Bruker’s advanced biophysical tools, such as NMR, mass spectrometry, and single-cell biology techniques, NovAliX will enhance its drug discovery services, from target assessment to lead optimization.

Joint innovation efforts will include NMR studies on protein and RNA structures, X-ray crystallography for structure-guided drug discovery, and high-throughput SPR for kinetics and binding studies. The partnership will also explore novel therapeutic peptides and oligonucleotides, as well as unique research on intrinsically disordered proteins for condensate biology.

Looking ahead, Bruker and NovAliX plan to establish the Biophysics Institute for Biomedical Research (IBRB) in Strasbourg by 2026. This institute will foster collaboration between biotechs, start-ups, and academic groups, driving innovation in biophysics and drug discovery.

Stephan Jenn, President of NovAliX, emphasized that the partnership will strengthen their leadership in biophysics and drug discovery, while Dr. Falko Busse, President of Bruker BioSpin Group, highlighted the potential to support the discovery of new medicines through advanced biophysical tools.

Financial details of the investment were not disclosed. NovAliX has over 430 employees across its European R&D and CRO service sites, and is expanding its reach in the U.S. and Japan.